Neutropenia como efecto adverso del tratamiento quimioterápico en pacientes con cáncer

This research was performed with the objective to know the current aspects related to the presence of neutropenia as an unwanted effect of the use of chemotherapy in patients with oncoproliferative processes, as this event occurs in a significant number of them, and few receive active prophylaxis, favoring the emergence complications that worsen the prognosis, delay the treatment and even cause death. This research makes reference to a literature review of national and international experiences, some definitions and clinical-epidemiological approaches are discussed, plus several new treatment techniques. It was carried out a review of PubMed, LILACS and CUMED databases since 2010 to 2014; other resources were consulted on the Internet as web pages of institutions and associations of Biomedical Sciences. Both review and original articles were included. It was concluded that this decrease in neutrophils varies according to the individual characteristics of the patient, the type of treatment, and the stage of disease, for which there have been developed innovative techniques for its management, proving efficiency and safety in neutropenic patients.